Data-driven biopharmaceutical company focused on identifying, enhancing, and commercializing high-potential therapeutic assets through a combination of artificial intelligence, scientific innovation, and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company leverages AI-driven analysis, solid-form chemistry, and asset repositioning strategies to unlock additional value from clinically validated drug candidates. Rather than pursuing traditional, capital-intensive drug development, CDT Equity focuses on generating intellectual property, expanding therapeutic applications, and out-licensing assets to pharmaceutical partners for later-stage development and commercialization. Headquartered in Naples, Florida and listed on the NASDAQ, CDT Equity is building a diversified portfolio across autoimmune diseases, oncology, dermatology, infertility, and animal health while maintaining a capital-efficient business model designed to accelerate innovation and create long-term shareholder value.